Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian Payne

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cancer Cell|April 5, 2003
Progress in immunoconjugate cancer therapeuticsGillian Payne
British Journal of Hospital Medicine (London, England : 2005)|April 9, 2015
Assessment of an incidental finding of left bundle-branch blockLuke Mair, David Warriner, Gillian Payne
The AAPS Journal|May 24, 2017
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical SamplesSven Loebrich, Mingfang Shen, Erika Cohen, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 25, 2019
Identification and characterization of co-purifying CHO host cell proteins in monoclonal antibody purification processXinrong Liu, Ying Chen, Yiwei Zhao, et al.
Molecular Cancer Therapeutics|May 27, 2020
An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor ActivitiesCéline Nicolazzi, Anne Caron, Alexia Tellier, et al.
Molecular Cancer Therapeutics|April 24, 2015
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing TumorsOlga Ab, Kathleen R Whiteman, Laura M Bartle, et al.
Bioconjugate Chemistry|March 24, 2011
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkageBrenda A Kellogg, Lisa Garrett, Yelena Kovtun, et al.
Heart (British Cardiac Society)|May 16, 2024
Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4)Mina Ghobrial, Hazel Haley, Rebecca Gosling, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancer Cell|April 5, 2003
Progress in immunoconjugate cancer therapeuticsGillian Payne
British Journal of Hospital Medicine (London, England : 2005)|April 9, 2015
Assessment of an incidental finding of left bundle-branch blockLuke Mair, David Warriner, Gillian Payne
The AAPS Journal|May 24, 2017
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical SamplesSven Loebrich, Mingfang Shen, Erika Cohen, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 25, 2019
Identification and characterization of co-purifying CHO host cell proteins in monoclonal antibody purification processXinrong Liu, Ying Chen, Yiwei Zhao, et al.
Molecular Cancer Therapeutics|May 27, 2020
An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor ActivitiesCéline Nicolazzi, Anne Caron, Alexia Tellier, et al.
Molecular Cancer Therapeutics|April 24, 2015
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing TumorsOlga Ab, Kathleen R Whiteman, Laura M Bartle, et al.
Bioconjugate Chemistry|March 24, 2011
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkageBrenda A Kellogg, Lisa Garrett, Yelena Kovtun, et al.
Heart (British Cardiac Society)|May 16, 2024
Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4)Mina Ghobrial, Hazel Haley, Rebecca Gosling, et al.
Pageof 1